MorphoSys AG: National Comprehensive Cancer Network Updates

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)

Related Keywords

Germany , Boston , Massachusetts , United States , Planegg , Bayern , Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Joe Horvat , Practice Research Clinical Haematology , Linkedin , Xencor Inc , Twitter , Drug Administration , Exchange Commission , Morphosys Us Inc , National Comprehensive Cancer Network , National Comprehensive Cancer , Clinical Practice Guidelines , B Cell Lymphomas , Preferred Regimen , Diffuse Largeb Cell Lymphoma , Diffuse Largeb Cell , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Morphosy Annual Report , Practice Research , Morphosys , Ational , Comprehensive , Dancer , Network , Updates , Resignation , Monjuvi , Tafasitamab , Wxix , Referred , Regimen , Linical , Practice , Guidelines , Ncology , Fell , Lymphomas ,